Showing results (21-30 of 48) with videos related to
Sort By:
Pageof 5
Digestive Diseases and Sciences|April 4, 2007
Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulinGuy W Neff, Nyingi Kemmer, Tiffany E Kaiser, et al.Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 9, 2004
Consumption of dietary supplements in a liver transplant populationGuy W Neff, Christopher O'Brien, Marzia Montalbano, et al.Journal of Clinical Gastroenterology|January 23, 2008
Adult onset urea cycle disorder in a patient with presumed hepatic encephalopathyMuslim Atiq, Andrew F Holt, Kamran Safdar, et al.Transplantation|November 20, 2013
Nonalcoholic fatty liver disease epidemic and its implications for liver transplantationNyingi Kemmer, Guy W Neff, Edson Franco, et al.Journal of Clinical Gastroenterology|October 21, 2011
Durability of rifaximin response in hepatic encephalopathyGuy W Neff, Michael Jones, Taylor Broda, et al.Nature Communications|September 18, 2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetesStephen A Harrison, Nadege Gunn, Guy W Neff, et al.Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 6, 2003
Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver diseaseGuy W Neff, Andrew Bonham, Andreas G Tzakis, et al.Nature Medicine|October 16, 2023
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialStephen A Harrison, Rebecca Taub, Guy W Neff, et al.The Annals of Pharmacotherapy|August 26, 2004
Sirolimus-associated hepatotoxicity in liver transplantationGuy W Neff, Phillip Ruiz, Juan R Madariaga, et al.Clinical and Molecular Hepatology|April 21, 2025
HTD1801 Demonstrates Promising Potential for Histologic Improvements in MASH in Both a Preclinical and Phase 2 StudyVincent Wai-Sun Wong, Guy W Neff, Adrian M Di Bisceglie, et al.Pageof 5